Literature DB >> 11737589

Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells.

Y Uchiyama-Tanaka1, H Matsubara, Y Nozawa, S Murasawa, Y Mori, A Kosaki, K Maruyama, H Masaki, Y Shibasaki, S Fujiyama, A Nose, O Iba, T Hasagawa, E Tateishi, S Higashiyama, T Iwasaka.   

Abstract

BACKGROUND: Angiotensin II (Ang II) has been implicated in the development of glomerulosclerosis by stimulating fibronectin (FN) synthesis. The processing and release of heparin binding-endothelin growth factor (HB-EGF) are activated by protein kinase C (PKC) and Ca2+ signaling. We studied the roles of HB-EGF and endothelial growth factor (EGF) receptor (EGFR) in Ang II-induced FN expression using mesangial cells.
METHODS: Mesangial cells were prepared from mouse kidneys by the explant method and cells were used at passages 4 and 5.
RESULTS: Ang II stimulated FN mRNA levels dose-dependently with a maximal increase (3.4-fold) after 12 hours of incubation. This action was completely inhibited by PKC inhibitors and slightly blocked by Ca2+ chelating agents. FN mRNA accumulation by Ang II was abolished by tyrosine kinase inhibitors, a specific inhibitor for EGFR (AG1478) and extracellular signal-regulated kinase (ERK) inactivation. Addition of neutralizing anti-HB-EGF antibody, as well as pretreatment with heparin or the metalloproteinase inhibitor batimastat abolished induction of FN expression by Ang II. In mesangial cells stably transfected with a chimeric construct containing HB-EGF and alkaline phosphatase (ALP) genes, ALP activity in incubation medium was rapidly increased by Ang II (1.7-fold at 0.5 min) and reached a 4.1-fold increase at two minutes. Ang II phosphorylated EGFR (maximal at 2 min) and ERK (maximal at 8 min) in a PKC- and metalloproteinase-dependent manner. Ang II stimulated the expression and release of transforming growth factor-beta (TGF-beta) via EGFR-mediated signaling, and the released TGF-beta also contributed to Ang II-mediated FN expression via EGFR transactivation.
CONCLUSIONS: Ang II-mediated FN expression was regulated by autocrine effects of HB-EGF and TGF-beta, suggesting a novel paradigm for cross-talk between Ang II and growth factor receptor signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737589     DOI: 10.1046/j.1523-1755.2001.00067.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  20 in total

1.  Serial killer: angiotensin drives cardiac hypertrophy via TGF-beta1.

Authors:  Michael D Schneider
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  SREBP-1 Mediates Angiotensin II-Induced TGF-β1 Upregulation and Glomerular Fibrosis.

Authors:  Tony N Wang; Xing Chen; Renzhong Li; Bo Gao; Zahraa Mohammed-Ali; Chao Lu; Victoria Yum; Jeffrey G Dickhout; Joan C Krepinsky
Journal:  J Am Soc Nephrol       Date:  2014-11-14       Impact factor: 10.121

Review 3.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

4.  Regulated ADAM17-dependent EGF family ligand release by substrate-selecting signaling pathways.

Authors:  Michelle Dang; Nicole Armbruster; Miles A Miller; Efrain Cermeno; Monika Hartmann; George W Bell; David E Root; Douglas A Lauffenburger; Harvey F Lodish; Andreas Herrlich
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-29       Impact factor: 11.205

Review 5.  ADAM-17: the enzyme that does it all.

Authors:  Monika Gooz
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-04       Impact factor: 8.250

Review 6.  Role of Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Oxidative Stress-Associated Metabolic Diseases.

Authors:  Seonwook Kim; Venkateswaran Subramanian; Ahmed Abdel-Latif; Sangderk Lee
Journal:  Metab Syndr Relat Disord       Date:  2020-02-20       Impact factor: 1.894

7.  Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

Authors:  Jan M Williams; Jin Zhang; Paula North; Steven Lacy; Michael Yakes; Annette Dahly-Vernon; Richard J Roman
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

8.  Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis.

Authors:  Na Liu; Jian-Kan Guo; Maoyin Pang; Evelyn Tolbert; Murugavel Ponnusamy; Rujun Gong; George Bayliss; Lance D Dworkin; Haidong Yan; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

9.  A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation.

Authors:  Amee J George; Brooke W Purdue; Cathryn M Gould; Daniel W Thomas; Yanny Handoko; Hongwei Qian; Gregory A Quaife-Ryan; Kylie A Morgan; Kaylene J Simpson; Walter G Thomas; Ross D Hannan
Journal:  J Cell Sci       Date:  2013-09-17       Impact factor: 5.285

10.  Angiotensin II-induced hypertension regulates AT1 receptor subtypes and extracellular matrix turnover in mouse retinal pigment epithelium.

Authors:  Françoise Praddaude; Scott W Cousins; Christiane Pêcher; Maria E Marin-Castaño
Journal:  Exp Eye Res       Date:  2009-03-10       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.